Eurobio Scientific announced the launch of its new proprietary test EBS 1005, an antigen self-test developed to identify the presence of the SARS-CoV-2 coronavirus by simple nasal sampling. The proprietary EBS 1005 test received an exemption from the French health authority, ANSM, to be marketed until CE marking is obtained. It also received a similar waiver from German health authorities. The test is intended to be sold in boxes of 5 tests, directly by pharmacies or under government contracts. EBS 1005 includes 5 unit test kits, each including an instructions leaflet, a nasal swab to be inserted for only 2 to 3 centimeters into the nose, a ready-to-use reagent, and the test plate. Very easy to use with a minimally invasive sampling, the test gives a result in 10 minutes, with excellent performance (specificity> 99%, sensitivity> 93%). This test complements Eurobio Scientific's COVID diagnostics offering, which includes: PCR tests including the proprietary EBX range with, among others, a test for the detection and qualification of SARS-CoV-2 variants (EBX 046), automated serological tests, and another proprietary antigen test for healthcare professionals, EBS 1020.